The American journal of gastroenterology · 2019
Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pearlman Brian, Perrys Michael, Hinds Andrew
Аннотация
OBJECTIVES: Chronic hepatitis C-infected patients who do not respond to nonstructural 5A inhibitor-containing regimens have few treatment options. It is unclear if patients who fail glecaprevir/pibrentasvir (G/P) (Mavyret) can be re-treated with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) (Vosevi) because the latter's registration trials antedated the availability of the former.
METHODS: Adherent virologic failures to G/P were re-treated with 12 weeks of SOF/VEL/VOX, and all subjects underwent resistance testing at baseline and again with subsequent relapse.
RESULTS: Ninety-four percent of subjects achieved sustained virologic response with re-treatment, despite 90% of 31 subjects harboring nonstructural 5A inhibitor resistance-associated mutations at baseline.
DISCUSSION: SOF/VEL/VOX is an effective regimen for virologic failures to G/P.
METHODS: Adherent virologic failures to G/P were re-treated with 12 weeks of SOF/VEL/VOX, and all subjects underwent resistance testing at baseline and again with subsequent relapse.
RESULTS: Ninety-four percent of subjects achieved sustained virologic response with re-treatment, despite 90% of 31 subjects harboring nonstructural 5A inhibitor resistance-associated mutations at baseline.
DISCUSSION: SOF/VEL/VOX is an effective regimen for virologic failures to G/P.
Предметные рубрики MeSH
Aminoisobutyric AcidsAntiviral AgentsBenzimidazolesCarbamatesCyclopropanesDrug Resistance, ViralDrug Therapy, CombinationFemaleGenotypeHepacivirusHepatitis C, ChronicHeterocyclic Compounds, 4 or More RingsHumansLactams, MacrocyclicLeucineMacrocyclic CompoundsMaleProlinePyrrolidinesQuinoxalinesRNA, ViralSofosbuvirSulfonamidesSustained Virologic ResponseTreatment FailureTreatment OutcomeBenzopyrans